Hello dear reader! I was approached by the Ataxia Canada Foundation  to write a blog about my life with the disease. A blog that I will simply call Ataxia and I where I will tell my adventures with this unwanted and invasive condition, Friedreich’s Ataxia – or FA, a serious...

Neurocrine Biosciences and Voyager Therapeutic announced the formation of a strategic collaboration focused on the development and commercialization of Voyager’s gene therapy programs, VY-AADC for Parkinson’s disease and VY-FXN01 for Friedreich’s ataxia, as well as rights to two programs to be determined. This collaboration combines Neurocrine Biosciences’ expertise in neuroscience,...

Ataxia Canada: position posted on December 17, 2018. Closing date: Friday, December 28, 2018 at 4 pm Ataxia Canada – Claude St-Jean Foundation is looking for an intern – project manager Our foundation wishes to support the young talents of our organization in their quest for gainful employment. We therefore...

Dear members, You are cordially invited to the annual general assembly of the members of Ataxia Canada-Claude St-Jean Foundation. The meeting will be held in Montreal at the Centre for Sustainable Development located at 50 Sainte-Catherine street west, 2nd Floor on Sunday November 18th, 2018 at 1PM. This assembly will...

The article Cerebellar ataxia and intrathecal baclofen therapy: Focus on patients’ experiments, published in the online journal PLOS ONE, presents the results of a qualitative research on the impact of family ataxias on persons’ life. “The aim of this study was to elucidate and better understand patients´ experiences of living...

Resume from the Friedreich’s Ataxia News article, Specific Cytokines Therapy Protected Neurons in Humanized Mouse Study “A cocktail of clinically approved cytokines for other diseases shows promising neuro-protective effects in a Friedreich’s ataxia (FA) humanized mouse model. The study, “Cytokine therapy-mediated neuroprotection in a Friedreich’s ataxia mouse model” was published...